Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


GUIDELINE TITLE

Management of persons with psychoses.

BIBLIOGRAPHIC SOURCE(S)

  • Veterans Administration, Department of Defense. Management of persons with psychoses. Washington (DC): Department of Veteran Affairs; 2004 May. Various p.

REFERENCES SUPPORTING THE RECOMMENDATIONS

  • Anthony WA, Rogers ES, Cohen M, Davies RR. Relationships between psychiatric symptomatology, work skills, and future vocational performance. Psychiatr Serv 1995 Apr;46(4):353-8. PubMed


  • Anton RF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 1995 Feb;19(1):92-9. PubMed


  • Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997 Aug 15;42(4):233-46. PubMed


  • Azorin JM, Spiegel R, Remington G, Vanelle JM, Pere JJ, Giguere M, Bourdeix I. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 2001 Aug;158(8):1305-13. PubMed


  • Azrin NH, Teichner G. Evaluation of an instructional program for improving medication compliance for chronically mentally ill outpatients. Behav Res Ther 1998 Sep;36(9):849-61. PubMed


  • Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988 Jan;45(1):79-91. [200 references] PubMed


  • Barrowclough C, Tarrier N, Lewis S, Sellwood W, Mainwaring J, Quinn J, Hamlin C. Randomised controlled effectiveness trial of a needs-based psychosocial intervention service for carers of people with schizophrenia. BJP Rev Books 1999 Jun;174:505-11. PubMed


  • Becker DR, Drake RE, Bond GR, Xie H, Dain BJ, Harrison K. Job terminations among persons with severe mental illness participating in supported employment. Community Ment Health J 1998 Feb;34(1):71-82. PubMed


  • Bell MD, Lysaker PH, Milstein RM. Clinical benefits of paid work activity in schizophrenia. Schizophr Bull 1996;22(1):51-67. PubMed


  • Bell MD, Lysaker PH. Clinical benefits of paid work activity in schizophrenia: 1-year followup. Schizophr Bull 1997;23(2):317-28. PubMed


  • Bell R, McLaren A, Galanos J, Copolov D. The clinical use of plasma clozapine levels. Aust N Z J Psychiatry 1998 Aug;32(4):567-74. [54 references] PubMed


  • Bellack AS, Mueser KT. Psychosocial treatment for schizophrenia. Schizophr Bull 1993;19(2):317-36. [167 references] PubMed


  • Bellack AS, Turner SM, Hersen M, Luber RF. An examination of the efficacy of social skills training for chronic schizophrenic patients. Hosp Community Psychiatry 1984 Oct;35(10):1023-8. PubMed


  • Bentall RP, Higson PJ, Lowe CF. Teaching self-instructions to chronic schizophrenic patients. Efficacy and generalization. Behav Psychother 1987;15:58-76.


  • Blankertz L, Robinson S. Adding a vocational focus to mental health rehabilitation. Psychiatr Serv 1996 Nov;47(11):1216-22. PubMed


  • Blow FC, Ullman E, Barry KL, Bingham CR, Copeland LA, McCormick R, Van Stone W. Effectiveness of specialized treatment programs for veterans with serious and persistent mental illness: a three-year follow-up. Am J Orthopsychiatry 2000 Jul;70(3):389-400. PubMed


  • Bouchard RH, Merette C, Pourcher E, Demers MF, Villeneuve J, Roy-Gagnon MH, Gauthier Y, Cliche D, Labelle A, Filteau MJ, Roy MA, Maziade M. Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group. J Clin Psychopharmacol 2000 Jun;20(3):295-304. PubMed


  • Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994 Jan;151(1):20-6. PubMed


  • Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 1999 Feb 15;45(4):403-11. PubMed


  • Casey JF, Lasky JJ, Klett CJ, Hollister LE. Treatment of schizophrenic reactions with phenothiazine derivatives. A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine, and phenobarbital. Am J Psychiatry 1960 Aug;117:97-105. PubMed


  • Chandler D, Meisel J, Hu T, McGowen M, Madison K. A capitated model for a cross-section of severely mentally ill clients: hospitalization. Community Ment Health J 1998 Feb;34(1):13-26. PubMed


  • Chandler D, Meisel J, Hu TW, McGowen M, Madison K. Client outcomes in a three-year controlled study of an integrated service agency model. Psychiatr Serv 1996 Dec;47(12):1337-43. PubMed


  • Chandler D, Meisel J, McGowen M, Mintz J, Madison K. Client outcomes in two model capitated integrated service agencies. Psychiatr Serv 1996 Feb;47(2):175-80. PubMed


  • Chandler D, Quinlivan R. Social skills training modules in an intensive community support program. Admin Policy Mental Health 2000 Mar;27(4):211-20. PubMed


  • Chaplin R, Kent A. Informing patients about tardive dyskinesia. Controlled trial of patient education. BJP Rev Books 1998 Jan;172:78-81. PubMed


  • Chinman MJ, Rosenheck R, Lam JA. The case management relationship and outcomes of homeless persons with serious mental illness. Psychiatr Serv 2000 Sep;51(9):1142-7. PubMed


  • Claghorn J, Honigfeld G, Abuzzahab FS Sr, Wang R, Steinbook R, Tuason V, Klerman G. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987 Dec;7(6):377-84. PubMed


  • Clark RE, Xie H, Becker DR, Drake RE. Benefits and costs of supported employment from three perspectives. J Behav Health Serv Res 1998 Feb;25(1):22-34. PubMed


  • Collins PY, Geller PA, Miller S, Toro P, Susser ES. Ourselves, our bodies, our realities: an HIV prevention intervention for women with severe mental illness. J Urban Health 2001 Mar;78(1):162-75. PubMed


  • Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, Hegerty J, Love R, Gounaris C, Zaremba S. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998 Jul;155(7):914-20. PubMed


  • Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol Med 2000 Jan;30(1):95-105. PubMed


  • Cox GB, Walker RD, Freng SA, Short BA, Meijer L, Gilchrist L. Outcome of a controlled trial of the effectiveness of intensive case management for chronic public inebriates. J Stud Alcohol Drugs 1998 Sep;59(5):523-32. PubMed


  • Creed F, Mbaya P, Lancashire S, Tomenson B, Williams B, Holme S. Cost effectiveness of day and inpatient psychiatric treatment: results of a randomised controlled trial. BMJ 1997 May 10;314(7091):1381-5. PubMed


  • Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. BJP Rev Books 1986 Feb;148:120-7. PubMed


  • Crowther RE, Marshall M, Bond GR, Huxley P. Helping people with severe mental illness to obtain work: systematic review. BMJ 2001 Jan 27;322(7280):204-8, tables. PubMed


  • Culhane DP, Metraux M, Hadley T. The impact of supportive housing for homeless people with severe mental illness on the utilization of the public health, corrections, and emergency shelter systems: the New York-New York initiative. Housing policy debate. 2001.


  • Davis JM, Janicak PG, Singla A, et al. Maintenance antipsychotic medication. In: Barnes TR, editor(s). Antipsychotic drugs and their side effects. New York (NY): Academic Press; 1993. p. 182-203.


  • Delaney C. Reducing recidivism: medication versus psychosocial rehabilitation. J Psychosoc Nurs Ment Health Serv 1998 Nov;36:28-34. PubMed


  • Dickey B, Gonzalez O, Latimer E, Powers K, Schutt R, Goldfinger S. Use of mental health services by formerly homeless adults residing in group and independent housing. Psychiatr Serv 1996 Feb;47(2):152-8. PubMed


  • Dickey B, Latimer E, Powers K, Gonzalez O, Goldfinger SM. Housing costs for adults who are mentally ill and formerly homeless. J Ment Health Adm 1997;24(3):291-305. PubMed


  • Dixon L, Adams C, Lucksted A. Update on family psychoeducation for schizophrenia. Schizophr Bull 2000;26(1):5-20. [50 references] PubMed


  • Dixon L, Goldberg R, Lehman A, McNary S. The impact of health status on work, symptoms, and functional outcomes in severe mental illness. J Nerv Ment Dis 2001 Jan;189(1):17-23. PubMed


  • Dixon L, Weiden P, Torres M, Lehman A. Assertive community treatment and medication compliance in the homeless mentally ill. Am J Psychiatry 1997 Sep;154(9):1302-4. PubMed


  • Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995;21(4):567-77. [40 references] PubMed


  • Drake RE, Becker DR, Biesanz JC, Torrey WC, McHugo GJ, Wyzik PF. Rehabilitative day treatment vs. supported employment: I. Vocational outcomes. Community Ment Health J 1994 Oct;30(5):519-32. PubMed


  • Drake RE, McHugo GJ, Bebout RR, Becker DR, Harris M, Bond GR, Quimby E. A randomized clinical trial of supported employment for inner-city patients with severe mental disorders. Arch Gen Psychiatry 1999 Jul;56(7):627-33. PubMed


  • Drake RE, McHugo GJ, Becker DR, Anthony WA, Clark RE. The New Hampshire study of supported employment for people with severe mental illness. J Consult Clin Psychol 1996 Apr;64(2):391-9. PubMed


  • Drake RE, McHugo GJ, Clark RE, Teague GB, Xie H, Miles K, Ackerson TH. Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: a clinical trial. Am J Orthopsychiatry 1998 Apr;68(2):201-15. PubMed


  • Dyck DG, Short RA, Hendryx MS, Norell D, Myers M, Patterson T, McDonell MG, Voss WD, McFarlane WR. Management of negative symptoms among patients with schizophrenia attending multiple-family groups. Psychiatr Serv 2000 Apr;51(4):513-9. PubMed


  • Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000 May;15(3):121-31. PubMed


  • Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999;25(4):721-9. PubMed


  • Essock SM, Frisman LK, Kontos NJ. Cost-effectiveness of assertive community treatment teams. Am J Orthopsychiatry 1998 Apr;68(2):179-90. PubMed


  • Fairweather GW. Community life for the mentally ill: an alternative to institutional care. Chicago (IL): Aldine Publishing Company; 1969.


  • Gater R, Goldberg D, Jackson G, Jennett N, Lowson K, Ratcliffe J, Saraf T, Warner R. The care of patients with chronic schizophrenia: a comparison between two services. Psychol Med 1997 Nov;27(6):1325-36. PubMed


  • Glazer WM, Dickson RA. Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psychiatry 1998;59 Suppl 3:8-14. PubMed


  • Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacologia 1995 Feb;117(4):417-23. PubMed


  • Goldberg RW, Lucksted A, McNary S, Gold JM, Dixon L, Lehman A. Correlates of long-term unemployment among inner-city adults with serious and persistent mental illness. Psychiatr Serv 2001 Jan;52(1):101-3. PubMed


  • Goldfinger SM, Schutt RK, Tolomiczenko GS, Seidman L, Penk WE, Turner W, Caplan B. Housing placement and subsequent days homeless among formerly homeless adults with mental illness. Psychiatr Serv 1999 May;50(5):674-9. PubMed


  • Gowdy EA, Carlson L. 'Work is the best medicine I can have': identifying best practices in supported employment for people with psychiatric disabilities. Unpublished ms. 2001.


  • Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia. Am J Psychiatry 1996 Mar;153(3):321-30. [73 references] PubMed


  • Hajagos K, Geiser P, Parker B, Tesfa A. Safer-sex education for persons with mental illness. J Psychosoc Nurs Ment Health Serv 1998 Aug;36(8):33-7. PubMed


  • Harris GT, Rice ME. Risk appraisal and management of violent behavior. Psychiatr Serv 1997 Sep;48(9):1168-76. [132 references] PubMed


  • Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry 1996 Sep;153(9):1195-201. PubMed


  • Hastings JE, Hamberger LK. Sociodemographic predictors of violence. Psychiatr Clin North Am 1997 Jun;20(2):323-35. PubMed


  • Havassy BE, Shopshire MS, Quigley LA. Effects of substance dependence on outcomes of patients in a randomized trial of two case management models. Psychiatr Serv 2000 May;51(5):639-44. PubMed


  • Hawks D. How to profit from sensible drinking. Addiction 1994 Mar;89(3):351. PubMed


  • Hayes RL, Halford WK. Time use of unemployed and employed single male schizophrenia subjects. Schizophr Bull 1996;22(4):659-69. PubMed


  • Herz M. Prodromal symptoms and prevention of relapse in schizophrenia. J Clin Psychiatry 1985 Nov;46(11 Pt 2):22-5. PubMed


  • Herz MI, Endicott J, Spitzer RL, Mesnikoff A. Day versus inpatient hospitalization: a controlled study. Am J Psychiatry 1971 Apr;127(10):1371-82. PubMed


  • Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Ulrich RF, Carter M. Family psychoeducation. Arch Gen Psychiatry 1991 Apr;48(4):340-7. PubMed


  • Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979 Nov;36(12):1283-94. PubMed


  • Hurlburt MS, Hough RL, Wood PA. Effects of substance abuse on housing stability of homeless mentally Ill persons in supported housing. Psychiatr Serv 1996 Jul;47(7):731-6. PubMed


  • Issakidis C, Sanderson K, Teesson M, Johnston S, Buhrich N. Intensive case management in Australia: a randomized controlled trial. Acta Psychiatr Scand 1999;99(5):360-7. PubMed


  • Janicak PG, Davis JM, Preskorn SH, et al. Priniciples and practice of psychopharmacotherapy. Baltimore (MD): Williams & Wilkins; 1993.


  • Janicak PG, Javaid JI, Sharma RP, Comaty JE, Peterson J, Davis JM. Trifluoperazine plasma levels and clinical response. J Clin Psychopharmacol 1989 Oct;9(5):340-6. PubMed


  • Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999 Jun;47(6):716-9. PubMed


  • Jones C, Cormac I, Mota J, et al. Cognitive behaviour therapy for schizophrenia. In: The Cochrane Library [internet]. Issue 2. Oxford: Update Software; 1999 


  • Joy CB, Adams CE, Rice K. Crisis intervention for people with severe mental illness. In: The Cochrane Library [internet]. Issue 2. Oxford: Update Software; 1999 


  • Kahn RS, Davis KL. New developments in dopamine and schizophrenia. In: Bloom FE, Kupfer D, editor(s). Psychopharmacology: the fourth generation of progress. New York (NY): Raven Press; 1995. p. 1192-203.


  • Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988 Sep;45(9):789-96. PubMed


  • Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 1982 Jan;39(1):70-3. PubMed


  • Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive dyskinesia. J Clin Psychiatry 1993 Sep;54(9):327-30. PubMed


  • Kay SR, Wolkenfeld F, Murrill LM. Profiles of aggression among psychiatric patients. I. Nature and prevalence. J Nerv Ment Dis 1988 Sep;176(9):539-46. PubMed


  • Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacologia 1998 Nov;140(2):173-84. PubMed


  • Kelly JA, McAuliffe TL, Sikkema KJ, Murphy DA, Somlai AM, Mulry G, Miller JG, Stevenson LY, Fernandez MI. Reduction in risk behavior among adults with severe mental illness who learned to advocate for HIV prevention. Psychiatr Serv 1997 Oct;48(10):1283-8. PubMed


  • Knapp M, Beecham J, Koutsogeorgopoulou V, Hallam A, Fenyo A, Marks IM, Connolly J, Audini B, Muijen M. Service use and costs of home-based versus hospital-based care for people with serious mental illness. BJP Rev Books 1994 Aug;165(2):195-203. PubMed


  • Kopelowicz A, Wallace CJ, Zarate R. Teaching psychiatric inpatients to re-enter the community: a brief method of improving the continuity of care. Psychiatr Serv 1998 Oct;49(10):1313-6. PubMed


  • Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002 Aug 3;325(7358):243. PubMed


  • Krakowski M, Czobor P, Chou JC. Course of violence in patients with schizophrenia: relationship to clinical symptoms. Schizophr Bull 1999;25(3):505-17. PubMed


  • Kuipers E, Fowler D, Garety P, Chisholm D, Freeman D, Dunn G, Bebbington P, Hadley C. London-east Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. III: Follow-up and economic evaluation at 18 months. BJP Rev Books 1998 Jul;173:61-8. PubMed


  • Langsley DG, Machotka P, Flomenhaft K. Avoiding mental hospital admission: a follow-up study. Am J Psychiatry 1971 Apr;127(10):1391-4. PubMed


  • Laskey JJ, Klett CJ. Drug treatment of schizophrenic patient. Dis Nerv Syst 1962;23:698.


  • Leclerc C, Lesage AD, Ricard N, Lecomte T, Cyr M. Assessment of a new rehabilitative coping skills module for persons with schizophrenia. Am J Orthopsychiatry 2000 Jul;70(3):380-8. PubMed


  • Lecomte T, Cyr M, Lesage AD, Wilde J, Leclerc C, Ricard N. Efficacy of a self-esteem module in the empowerment of individuals with schizophrenia. J Nerv Ment Dis 1999 Jul;187(7):406-13. PubMed


  • Lehman AF, Dixon LB, Kernan E, DeForge BR, Postrado LT. A randomized trial of assertive community treatment for homeless persons with severe mental illness. Arch Gen Psychiatry 1997 Nov;54(11):1038-43. PubMed


  • Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24(1):1-10. PubMed


  • Levinson DF, Simpson GM, Lo ES, Cooper TB, Singh H, Yadalam K, Stephanos MJ. Fluphenazine plasma levels, dosage, efficacy, and side effects. Am J Psychiatry 1995 May;152(5):765-71. PubMed


  • Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 1999 Aug;156(8):1138-48. [64 references] PubMed


  • Liberman RP, Lillie F, Falloon IR, Harpin RE, Hutchinson W, Stoute B. Social skills training with relapsing schizophrenics. An experimental analysis. Behav Modif 1984 Apr;8(2):155-79. PubMed


  • Liberman RP, Wallace CJ, Blackwell G, Kopelowicz A, Vaccaro JV, Mintz J. Skills training versus psychosocial occupational therapy for persons with persistent schizophrenia. Am J Psychiatry 1998 Aug;155(8):1087-91. PubMed


  • Link BG, Stueve A, Phelan J. Psychotic symptoms and violent behaviors: probing the components of "threat/control-override" symptoms. Soc Psychiatry Psychiatr Epidemiol 1998 Dec;33 Suppl 1:S55-60. PubMed


  • Lipton FR, Siegel C, Hannigan A, Samuels J, Baker S. Tenure in supportive housing for homeless persons with severe mental illness. Psychiatr Serv 2000 Apr;51(4):479-86. PubMed


  • Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992 Sep;149(9):1183-8. PubMed


  • Mann JJ, Waternaux C, Haas GL, Malone KM. Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 1999 Feb;156(2):181-9. PubMed


  • Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994 Jun;151(6):825-35. PubMed


  • Marder SR, Wirshing WC, Mintz J, McKenzie J, Johnston K, Eckman TA, Lebell M, Zimmerman K, Liberman RP. Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Am J Psychiatry 1996 Dec;153(12):1585-92. PubMed


  • Mares A, McGuire J. Reducing psychiatric hospitalization among mentally ill veterans living in board-and-care homes. Psychiatr Serv 2000 Jul;51(7):914-21. PubMed


  • Mari JJ, Streiner D. The effects of family intervention on those with schizophrenia. In: The Cochrane Library [internet]. Issue 2. Oxford: Update Software; 1996 


  • Marshall M, Crowther R, Almaraz-Serrano A, Creed F, Sledge W, Kluiter H, Roberts C, Hill E, Wiersma D, Bond GR, Huxley P, Tyrer P. Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational rehabilitation; (3) day hospital versus outpatient care. Health Technol Assess 2001;5(21):1-75. [66 references] PubMed


  • May PR, Tuma AH, Yale C, Potepan P, Dixon WJ. Schizophrenia--a follow-up study of results of treatment. Arch Gen Psychiatry 1976 Apr;33(4):481-6. PubMed


  • Mayfield D, McLeod G, Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry 1974 Oct;131(10):1121-3. PubMed


  • McHugo GJ, Drake RE, Teague GB, Xie H. Fidelity to assertive community treatment and client outcomes in the New Hampshire dual disorders study. Psychiatr Serv 1999 Jun;50(6):818-24. PubMed


  • Medalia A, Aluma M, Tryon W, Merriam AE. Effectiveness of attention training in schizophrenia. Schizophr Bull 1998;24(1):147-52. PubMed


  • Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003 Jan;60(1):82-91. PubMed


  • Merinder LB, Viuff AG, Laugesen HD, Clemmensen K, Misfelt S, Espensen B. Patient and relative education in community psychiatry: a randomized controlled trial regarding its effectiveness. Soc Psychiatry Psychiatr Epidemiol 1999 Jun;34(6):287-94. PubMed


  • Midanik LT, Tam TW, Greenfield TK, Caetano R. Risk functions for alcohol-related problems in a 1988 US national sample. Addiction 1996 Oct;91(10):1427-37; discussion 1439-. PubMed


  • Mowbray C. The Michigan Supported Education Program. Psychiatr Serv 2000 Nov;51(11):1355-7. PubMed


  • Mowbray CT, Collins M, ByBee D. Supported education for individuals with psychiatric disabilities: long-term outcomes from an experimental study. Soc Work Res 1999;23(2):89-100.


  • Mueser KT, Kosmidis MH, Sayers MD. Symptomatology and the prediction of social skills acquisition in schizophrenia. Schizophr Res 1992 Oct;8(1):59-68. PubMed


  • Mueser KT, Levine S, Bellack AS, Douglas MS, Brady EU. Social skills training for acute psychiatric inpatients. Hosp Community Psychiatry 1990 Nov;41(11):1249-51. PubMed


  • Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002 Apr;59(4):337-45. [127 references] PubMed


  • Owen RR, Thrush CR, Kirchner JE, Fischer EP, Booth BM. Performance measurement for schizophrenia: adherence to guidelines for antipsychotic dose. Int J Qual Health Care 2000 Dec;12(6):475-82. PubMed


  • Pharoah FM, Mari JJ, Streiner D. Family intervention fro schizophrenia. In: The Cochrane Library [internet]. Issue 2. Oxford: Update Software; 1999 


  • Phillips SD, Burns BJ, Edgar ER, Mueser KT, Linkins KW, Rosenheck RA, Drake RE, McDonel Herr EC. Moving assertive community treatment into standard practice. Psychiatr Serv 2001 Jun;52(6):771-9. [68 references] PubMed


  • Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry 1992 May;49(5):345-53. PubMed


  • Rabinowitz J, Avnon M, Rosenberg V. Effect of clozapine on physical and verbal aggression. Schizophr Res 1996 Dec 15;22(3):249-55. PubMed


  • Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr Serv 1998 Aug;49(8):1029-33. PubMed


  • Remington G, Kapur S, Zipursky RB. Pharmacotherapy of first-episode schizophrenia. Br J Psychiatry Suppl 1998;172(33):66-70. [29 references] PubMed


  • Roberts JS, Blow FC, Copeland LA, Barry KL, Van Stone W. Age-group differences in treatment outcomes for male veterans with severe schizophrenia: a three-year longitudinal study. J Geriatr Psychiatry Neurol 2000 Summer;13(2):78-86. PubMed


  • Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999 Apr;156(4):544-9. PubMed


  • Room R, Bondy SJ, Ferris J. The risk of harm to oneself from drinking, Canada 1989. Addiction 1995 Apr;90(4):499-513. PubMed


  • Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997 Sep 18;337(12):809-15. PubMed


  • Rosenheck RA, Neale MS. Cost-effectiveness of intensive psychiatric community care for high users of inpatient services. Arch Gen Psychiatry 1998 May;55(5):459-66. PubMed


  • Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999 Jan;156(1):79-87. PubMed


  • Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction 1993 Jun;88(6):791-804. PubMed


  • Schorling JB, Buchsbaum D. Screening for alcohol and drug abuse. Med Clin North Am 1997 Jul;81(4):845-65. [97 references] PubMed


  • Sensky T, Turkington D, Kingdon D, Scott JL, Scott J, Siddle R, O'Carroll M, Barnes TR. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch Gen Psychiatry 2000 Feb;57(2):165-72. PubMed


  • Sernyak MJ, Desai R, Stolar M, Rosenheck R. Impact of clozapine on completed suicide. Am J Psychiatry 2001 Jun;158(6):931-7. PubMed


  • Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002 Apr;159(4):561-6. PubMed


  • Siris SG, Bermanzohn PC, Mason SE, Shuwall MA. Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch Gen Psychiatry 1994 Feb;51(2):109-15. PubMed


  • Solomon P, Draine J, Delaney MA. The working alliance and consumer case management. J Ment Health Adm 1995 Spring;22(2):126-34. PubMed


  • Solomon P, Draine J, Mannion E, Meisel M. Effectiveness of two models of brief family education: retention of gains by family members of adults with serious mental illness. Am J Orthopsychiatry 1997 Apr;67(2):177-86. PubMed


  • Sovani A, Thatte S. Effects of psychosocial interventions on motor speed and accuracy of chronic positive, negative, and mixed symptom schizophrenics. Int J Soc Psychiatry 1998 Summer;44(2):117-26. PubMed


  • Substance Abuse and Mental Health Services Administration (SAMHSA). Assessment and treatment of patients with coexisting mental illness and alcohol and other drug abuse. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment; 1995. 153 p.  (Treatment improvement protocol (TIP) series; no. 9). [104 references]


  • Tarrier N, Wittkowski A, Kinney C, McCarthy E, Morris J, Humphreys L. Durability of the effects of cognitive-behavioural therapy in the treatment of chronic schizophrenia: 12-month follow-up. BJP Rev Books 1999 Jun;174:500-4. PubMed


  • Tarrier N, Yusupoff L, Kinney C, McCarthy E, Gledhill A, Haddock G, Morris J. Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic schizophrenia. BMJ 1998 Aug 1;317(7154):303-7. PubMed


  • Tarrier N. Intensive cognitive behaviour therapy for chronic schizophrenia: specific effect of cognitive behaviour therapy for schizophrenia is not proved: author's reply. BMJ 1999;


  • Thienhaus OJ, Piasecki M. Assessment of psychiatric patients' risk of violence toward others. Psychiatr Serv 1998 Sep;49(9):1129-30, 1147. PubMed


  • Tyrer P, Evans K, Gandhi N, Lamont A, Harrison-Read P, Johnson T. Randomised controlled trial of two models of care for discharged psychiatric patients. BMJ 1998 Jan 10;316(7125):106-9. PubMed


  • Tyrer P, Hassiotis A, Ukoumunne O, Piachaud J, Harvey K. Intensive case management for psychotic patients with borderline intelligence. UK 700 Group. Lancet 1999 Sep 18;354(9183):999-1000. PubMed


  • USPSTF. Screening for suicide risk: guide to preventive services. 2nd ed. Baltimore (MD): U.S. Preventive Services Task Force; 1996.


  • Van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N. Neuroleptic plasma levels. Schizophr Bull 1991;17(2):197-216. [79 references] PubMed


  • Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. In: The Cochrane Library [internet]. Issue 2. Oxford: Update Software; 2000 


  • Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997 Nov;8(6):671-7. PubMed


  • Walsh E, Harvey K, White I, Manley C, Fraser J, Stanbridge S, Murray RM. Prevalence and predictors of parasuicide in chronic psychosis. UK700 group. Acta Psychiatr Scand 1999 Nov;100(5):375-82. PubMed


  • Weinhardt LS, Carey MP, Carey KB, Verdecias RN. Increasing assertiveness skills to reduce HIV risk among women living with a severe and persistent mental illness. J Consult Clin Psychol 1998 Aug;66(4):680-4. PubMed


  • Wilder JF, Levin G, Zwerling I. A two-year follow-up evaluation of acute psychotic patients treated in a day hospital. Am J Psychiatry 1966 Apr;122(10):1095-101. PubMed


  • Willenbring ML, Olson DH, Bielinski J. Integrated outpatients treatment for medically ill alcoholic men: results from a quasi-experimental study. J Stud Alcohol Drugs 1995 May;56(3):337-43. PubMed


  • Williams R. Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry 2001 Apr;62(4):282-9. [43 references] PubMed


  • Wirshing DA, Marshall BD Jr, Green MF, Mintz J, Marder SR, Wirshing WC. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 1999 Sep;156(9):1374-9. PubMed


  • Wykes T, Reeder C, Corner J, Williams C, Everitt B. The effects of neurocognitive remediation on executive processing in patients with schizophrenia. Schizophr Bull 1999;25(2):291-307. PubMed


© 1998-2009 National Guideline Clearinghouse

Date Modified: 2/16/2009

 

 

   
DHHS Logo